Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Trial of HER-2 B Cell Peptide Vaccine in Advanced Solid Tumors
NCT06414733Phase 1Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2029
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mvf-her-2 in breast cancer and esophageal cancer (2 arms). Primary endpoints: Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0 at 1 year, Humoral Immune Response at day 92 and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
mvf-her-2
03
Conditions
breast canceresophageal cancer
Beyond the preview
Go deeper on NCT06414733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414733.